Neurology:多范型经颅磁性刺激用于阿尔茨海默病与额颞叶痴呆患者的鉴别

2017-07-28 zhangfan MedSci原创

研究认为,多范型经颅磁性刺激是一种非侵入且可靠的区分阿尔茨海默病、额颞叶痴呆与健康人群的方法。该方法将进行大范围的临床验证以考察其作为临床诊断辅助工具的潜力

近日研究人员考察了多范型经颅磁性刺激(TMS) 对于阿尔茨海默病(AD)与额颞叶痴呆(FTD)的区分能力。

研究人员采用双脉冲TMS对参试人员进行短间隔抑制(SICI)和易化(ICF)、长间隔抑制以及短潜伏期传入抑制(SAI)以考察阿尔茨海默病、额颞叶痴呆与健康对照者皮质内回路活动的差异。研究的主要终点是多范型经颅磁性刺激的敏感性和特异性。

研究招募了175名患者,其中AD患者79人,FTD患者64人,健康对照者32人。研究发现,AD患者SAI信号显示出特异性损伤而FTD患者皮质内回路SICI-ICF功能显著异常。在最优模式下,TMS以91.8%的敏感性以及88.6%的特异性从AD患者中区分FTD患者;以84.8%的敏感性以及90.6%的特异性从健康人群中区分AD患者;以90.2%的敏感性以及78.1%的特异性区从健康人群中区分FTD患者。TMS的效果在轻症患者中得到了证实。

研究认为,多范型经颅磁性刺激是一种非侵入且可靠的区分阿尔茨海默病、额颞叶痴呆与健康人群的方法。该方法将进行大范围的临床验证以考察其作为临床诊断辅助工具的潜力。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000049, encodeId=4aa920000494b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Apr 30 22:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816781, encodeId=137b1816e816e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri May 25 14:36:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817804, encodeId=b67c181e804df, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Apr 01 12:36:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009080, encodeId=26a0200908055, content=<a href='/topic/show?id=3ed8e121172' target=_blank style='color:#2F92EE;'>#痴呆患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71211, encryptionId=3ed8e121172, topicName=痴呆患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue May 22 18:36:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470158, encodeId=b60014e015818, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sun Jul 30 00:36:00 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
    2018-04-30 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000049, encodeId=4aa920000494b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Apr 30 22:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816781, encodeId=137b1816e816e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri May 25 14:36:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817804, encodeId=b67c181e804df, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Apr 01 12:36:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009080, encodeId=26a0200908055, content=<a href='/topic/show?id=3ed8e121172' target=_blank style='color:#2F92EE;'>#痴呆患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71211, encryptionId=3ed8e121172, topicName=痴呆患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue May 22 18:36:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470158, encodeId=b60014e015818, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sun Jul 30 00:36:00 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2000049, encodeId=4aa920000494b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Apr 30 22:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816781, encodeId=137b1816e816e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri May 25 14:36:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817804, encodeId=b67c181e804df, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Apr 01 12:36:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009080, encodeId=26a0200908055, content=<a href='/topic/show?id=3ed8e121172' target=_blank style='color:#2F92EE;'>#痴呆患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71211, encryptionId=3ed8e121172, topicName=痴呆患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue May 22 18:36:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470158, encodeId=b60014e015818, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sun Jul 30 00:36:00 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2000049, encodeId=4aa920000494b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Apr 30 22:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816781, encodeId=137b1816e816e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri May 25 14:36:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817804, encodeId=b67c181e804df, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Apr 01 12:36:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009080, encodeId=26a0200908055, content=<a href='/topic/show?id=3ed8e121172' target=_blank style='color:#2F92EE;'>#痴呆患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71211, encryptionId=3ed8e121172, topicName=痴呆患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue May 22 18:36:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470158, encodeId=b60014e015818, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sun Jul 30 00:36:00 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2000049, encodeId=4aa920000494b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Apr 30 22:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816781, encodeId=137b1816e816e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri May 25 14:36:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817804, encodeId=b67c181e804df, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Apr 01 12:36:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009080, encodeId=26a0200908055, content=<a href='/topic/show?id=3ed8e121172' target=_blank style='color:#2F92EE;'>#痴呆患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71211, encryptionId=3ed8e121172, topicName=痴呆患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue May 22 18:36:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470158, encodeId=b60014e015818, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sun Jul 30 00:36:00 CST 2017, time=2017-07-30, status=1, ipAttribution=)]

相关资讯

Brain:不好好睡觉真会变傻

近日有研究显示,即使只是一个晚上的睡眠受到打扰,大脑中与阿尔茨海默病有关的蛋白也会增加。 这项研究可回答长期探讨的问题:睡眠受到打扰与阿尔茨海默病之间的相关性,有助于预防慢性睡眠剥夺(chronic sleep deprivation)的危害。

SCI REP:血浆生物标志物与阿尔茨海默病患者躁动和局部脑萎缩有关!

总之,受试者血浆中Aβ1-42/Aβ1-40之间的比值和簇集素水平可能与区域性脑萎缩不同模式之间存在相关性,这反过来又可能说明阿尔茨海默病患者的临床症状。

盘点:近期阿尔茨海默病重要研究进展一览

阿尔茨海默病是一种起病隐匿的渐进性发展的神经系统退行性疾病。临床初症状表现为记忆力下降、日常生活能力产生障碍,最终将卧床不起、大小便失禁,完全需要依赖家人的照顾,病因迄今未明。据估计,我国现有1000多万老年性痴呆患者,数量居全球之首,占全球总患者的1/4,而且每年平均有30万新发病例。这里梅斯小编整理了近期关于阿尔茨海默病的重要研究进展与大家一同分享。【1】葡萄糖在阿尔茨海默病中修饰氧化巨噬

Front. Aging Neurosci:阿尔茨海默病患者大脑中存在更多细菌!

近日,来自英国的研究人员使用第二代测序(NGS)检查阿尔茨海默病患者尸检大脑中的细菌。他们发现,与健康的大脑相比,阿尔茨海默症患者大脑细菌水平和菌种比例存在差异。这意味着细菌感染和大脑炎症可能在阿尔茨海默病的发生发展中具有一定作用。

Cell:单细胞测序鉴定了一种小胶质细胞对阿尔茨海默病起到保护作用

总的来说,这项研究确定了一种与神经变性相关的潜在保护性小胶质细胞类型,而这一发现与主流的小胶质细胞促进阿尔茨海默病的理论相反。这一发现进一步揭示了中枢神经免疫系统对于神经病变的复杂性。

阿尔茨海默病协会在美推出生活方式干预试验

阿尔茨海默病协会(Alzheimer's Association)今天宣布推出一项投资达2000万美元的两年期临床试验,检验多维生活方式干预是否能够预防认知衰退和痴呆,试验对象为2500名目前没有认知方面疾病症状但后期认知衰退风险会增加的老年人。 /* Style Definitions